These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32227504)

  • 1. Letter: immunogenicity of infliximab-ready for routine prediction?
    Amiot A
    Aliment Pharmacol Ther; 2020 Apr; 51(8):812. PubMed ID: 32227504
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: immunogenicity of infliximab-ready for routine prediction? Authors' reply.
    Wilson A; Peel C; Wang Q; Pananos AD; Kim RB
    Aliment Pharmacol Ther; 2020 Apr; 51(8):813-814. PubMed ID: 32227506
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?
    Orfanoudaki E; Drygiannakis I; Koutroubakis IE
    Aliment Pharmacol Ther; 2018 Nov; 48(9):1037-1038. PubMed ID: 30318690
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients.
    Fiorino G; Correale C; Radice S; Allocca M; Furfaro F; Gilardi D; Nagore D; Del Rio L; Pascual J; Martínez A; Danese S
    Aliment Pharmacol Ther; 2017 Nov; 46(9):903-905. PubMed ID: 29023889
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: immunogenicity of infliximab originator vs. CT-P13 in IBD patients-authors' reply.
    Komaki Y; Yamada A; Komaki F; Sakuraba A
    Aliment Pharmacol Ther; 2017 Nov; 46(9):905-906. PubMed ID: 29023885
    [No Abstract]   [Full Text] [Related]  

  • 6. Real-Life Efficacy, Immunogenicity and Safety of Biosimilar Infliximab.
    Vegh Z; Kurti Z; Lakatos PL
    Dig Dis; 2017; 35(1-2):101-106. PubMed ID: 28147369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
    Katsanos KH; Papamichael K; Cheifetz AS; Christodoulou DK
    Inflamm Bowel Dis; 2018 Feb; 24(3):465-466. PubMed ID: 29462402
    [No Abstract]   [Full Text] [Related]  

  • 9. Letter: SPOSIB SB2-a Sicilian prospective observational study of IBD patients treated with infliximab biosimilar SB2.
    Macaluso FS; Cappello M; Giuffrida E; Fries W; Centritto A; Privitera AC; Inserra G; Vassallo R; Magnano A; Vinci E; Garufi S; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Cottone M; Orlando A;
    Aliment Pharmacol Ther; 2019 Jan; 49(2):234-236. PubMed ID: 30589969
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
    Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
    J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab biosimilar CT-P13 for inflammatory bowel disease.
    Bonovas S; Peyrin-Biroulet L; Danese S
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):373-375. PubMed ID: 29606565
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L; Peyrin-Biroulet L
    Curr Med Chem; 2019; 26(2):270-279. PubMed ID: 27758715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Felwick R; Cummings JRF
    Aliment Pharmacol Ther; 2017 May; 45(10):1370-1371. PubMed ID: 28417492
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases - authors' reply.
    Komaki Y; Yamada A; Komaki F; Micic D; Ido A; Sakuraba A
    Aliment Pharmacol Ther; 2017 May; 45(10):1372. PubMed ID: 28417494
    [No Abstract]   [Full Text] [Related]  

  • 16. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
    Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
    Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z; Gonczi L; Lakatos PL
    Expert Opin Biol Ther; 2018 Jun; 18(6):633-640. PubMed ID: 29688797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of the biosimilar CT-P13.
    Yoo DH
    J Comp Eff Res; 2017 Nov; 6(8):693-712. PubMed ID: 29172717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, Pharmacokinetics, and Immunogenicity is Not Affected by Switching From Infliximab Originator to a Biosimilar in Pediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    Ther Drug Monit; 2019 Jun; 41(3):317-324. PubMed ID: 30633088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough?
    Allocca M; Fiorino G; Danese S
    Dig Dis Sci; 2017 Nov; 62(11):2964-2965. PubMed ID: 28776140
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.